AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16415377
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg atorvastatin per day
Trial: 12868251
Drug: Daily exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily exposure to a small, portable pulsing electromagnetic field generator
Trial: 11825313
Drug: Anti-oxidant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-oxidant therapy (specifics not provided)
Trial: 7936855
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D and phosphate therapy for 4.33 ± 2.19 years
Trial: 21767407
Drug: etoricoxib 120
RxNorm normalized name: etoricoxib 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 120 mg
Trial: 30590861
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention based on the Theory of Triadic Influence (TTI) including a 50 min motivational interview and online self-help material, with follow-up support via email and group therapy.
Trial: 28394521
Drug: Low dose-rate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low dose-rate brachytherapy using domestically manufactured I-125 seeds with a minimum therapeutic dose of 145 Gy, average of 57 seeds implanted (0.55 and 0.35 mCi per seed).
Trial: 26835147
Drug: Enteric-coated mycophenolate
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated mycophenolate sodium (EC-MPS) 1440 mg/day for first 6 months, then EC-MPS 720 mg/day until 12 months
Trial: 20109120
Drug: Ultra absorbency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra absorbency tampon (15 g to 18 g)
Trial: 20109120
Drug: Super-plus absorbency
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Super-plus absorbency tampon (12 g to 15 g)
Trial: 7675951
Drug: Caffeine 150
RxNorm normalized name: caffeine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 150 mg
Trial: 7529482
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (2 million IU before CPB, 500,000 IU/h until end of operation, 2 million IU added to the prime)
Trial: 1706665
Drug: IVGG plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVGG plus Aspirin (group G)
Trial: 12529740
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (group A)
Trial: 25649680
Drug: Once-daily risperidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily risperidone
Trial: 25649680
Drug: Once-daily olanzapine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily olanzapine
Trial: 25649680
Drug: Twice-daily risperidone
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily risperidone
Trial: 25649680
Drug: Twice-daily olanzapine
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily olanzapine
Trial: 23598785
Drug: Oral probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral probiotic (VSL3® Ferring), 2 tablets a day for 5 days, followed by 1 tablet daily for 10 days
Trial: 23598785
Drug: Vaginal clindamycin
RxNorm normalized name: clindamycin Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal clindamycin 100 mg daily for 15 days
Trial: 11374407
Drug: Steroid-free immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-free immunosuppression protocol
Trial: 8299543
Drug: Nurse acting
RxNorm normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse acting as case manager working in conjunction with family doctors and community agencies to implement a treatment plan for depression.
Trial: 8299543
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication (recommended introduction).
Trial: 3102407
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or no drug therapy
Trial: 23848141
Drug: Topical activated
RxNorm normalized name: collagen,activated Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical activated protein C (APC)
Trial: 18279739
Drug: Ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5 mg/day for 4 weeks
Trial: 10678603
Drug: Ultrasound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound therapy with neck-stretching exercises
Trial: 10678603
Drug: Trigger point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigger point injections with neck-stretching exercises
Trial: 28108429
Drug: Telerehabilitation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telerehabilitation treatment options with feedback and monitoring technology (FMT), video communication, and flexible exercise hours.
Trial: 11417951
Drug: On-line HDF
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-line HDF once weekly
Trial: 8277035
Drug: 0.1% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% tretinoin cream
Trial: 31868565
Drug: 0.025% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025% tretinoin cream
Trial: 2660996
Drug: Intranasal salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal salmon calcitonin (200 IU per day)
Trial: 27932067
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks
Trial: 12007948
Drug: High-dose-rate (HDR)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose-rate (HDR) brachytherapy
Trial: 7955291
Drug: HeartMate 1000
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HeartMate 1000 IP LVAD with dipyridamole plus aspirin
Trial: 7955291
Drug: HeartMate 1000
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HeartMate 1000 IP LVAD with miscellaneous agents
Trial: 3042938
Drug: Enteric-coated microsphere
RxNorm normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated microsphere preparation (Pancrease)
Trial: 18082664
Drug: Low-dose estrogen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose estrogen for 7 days during the hormone-free interval
Trial: 17349080
Drug: SYN treatment
RxNorm normalized name: Gel-Syn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYN treatment in cancer group
Trial: 17349080
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received encapsulated maltodextrin and 10 g of maltodextrin
Trial: 15058367
Drug: experimental toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental toothpaste formulation
Trial: 26264399
Drug: Exenatide (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (twice daily)
Trial: 15668637
Drug: Postoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative treatment
Trial: 9715761
Drug: Salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (50 micrograms twice daily for 4 weeks)
Trial: 7873290
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate 1000 micrograms/day (500 micrograms twice daily) as the sole corticosteroid therapy
Trial: 30125345
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with preoperative insulin resistance (IR)
Trial: 30125345
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with normal insulin sensitivity (IS)
Trial: 25761658
Drug: Functional beverage
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional beverage (FB) based on grape skin polyphenols, single-dose intake (187 mL)
Trial: 23481448
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of trivalent inactivated influenza vaccine
Trial: 23481448
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of trivalent inactivated influenza vaccine
Trial: 9221486
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg human calcitonin (hCT)
Trial: 1441864
Drug: Piroxicam 40
RxNorm normalized name: piroxicam 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 40 mg rectally 12 h and 1 h before surgery and 20 mg 24 h postoperatively
Trial: 3516580
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg fenoverine 3-times daily for 20 days
Trial: 8838779
Drug: Tacrine (Cognex)
RxNorm normalized name: tacrine Oral Capsule [Cognex]
DrugBank: Tacrine (DB00382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrine (Cognex) at a starting dose of 40 mg/day, increased by 40 mg/day every 6 weeks until target dose achieved.
Trial: 30863852
Drug: 2 weeks
RxNorm normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 weeks of oral 5FC and FLU
Trial: 28992261
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of measles vaccine (MV) at 4.5 and 9 months of age
Trial: 28992261
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of measles vaccine (MV) at 9 months of age
Trial: 26576710
Drug: Tanezumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab (200 μg/kg intravenous, 20 mg intravenous, 20 mg subcutaneous)
Trial: 17943541
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg micronized 17beta-estradiol daily plus 10 mg dydrogesterone for 14 days of each 28-day cycle (n = 44)
Trial: 17943541
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n = 36)
Trial: 16230985
Drug: CoQ10 supplementation
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CoQ10 supplementation (150 mg daily)
Trial: 16230985
Drug: CoQ10 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 (150 mg) plus vitamin E (1,000 IU daily)
Trial: 9138278
Drug: IFN‐alpha‐2a 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha‐2a 3 MU three times weekly for 22 weeks
Trial: 9138278
Drug: IFN‐alpha‐2a 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha‐2a 6 MU three times weekly for 22 weeks
Trial: 2195426
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin K1 administration
Trial: 30357360
Drug: Thrice-weekly haemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly haemodialysis (3×HD)
Trial: 30357360
Drug: Twice-weekly haemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly haemodialysis (2×HD)
Trial: 17156291
Drug: HIV vaccine
RxNorm normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV vaccine
Trial: 22634443
Drug: Vaccine recipients
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine recipients
Trial: 19858156
Drug: Standard parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard parenteral nutrition solution
Trial: 19858156
Drug: Aluminum-depleted parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum-depleted parenteral nutrition solutions
Trial: 17074322
Drug: Modified ovarian
RxNorm normalized name: Autologous, DNP-Modified Ovarian Cancer Vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified ovarian age-based stimulation with microdose GnRH agonist (GnRH-a) and 450-600 IU of gonadotropin daily.
Trial: 9233079
Drug: Training workshop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training workshop for selected members to spread knowledge and skills of oral rehydration therapy.
Trial: 29851791
Drug: Anti-TB therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TB therapy with isoniazid, rifampicin, ethambutol, and pyrazinamide for 6 months
Trial: 26047975
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg TA-8995
Trial: 23437399
Drug: Laboratory and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laboratory and Clinical Monitoring (LCM, 12-weekly CD4s)
Trial: 12728487
Drug: Fentanyl 0.3
RxNorm normalized name: fentanyl 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.3 ml (15 micrograms) added to 0.5% hyperbaric bupivacaine 2.0 ml
Trial: 12728487
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline 0.3 ml added to 0.5% hyperbaric bupivacaine 2.0 ml
Trial: 11483142
Drug: Neurocognitive enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurocognitive enhancement therapy (NET) plus work therapy (WT)
Trial: 11483142
Drug: Work therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Work therapy (WT) alone
Trial: 26056838
Drug: PVB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVB with catheter at level Th 4, 10 ml each of 1:2 mixture of bupivacaine 0.5% and lidocaine 2% with adrenaline injected at three different levels
Trial: 23165913
Drug: Lactitol treatment
RxNorm normalized name: Lactitol
DrugBank: Lactitol (DB12942)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactitol treatment
Trial: 21639927
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus cooling (target rectal temperature of 33-34°C for 72 hrs, started within 3 h of birth)
Trial: 16546486
Drug: PSE margarine
RxNorm normalized name: MARGARINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSE margarine (3 g)
Trial: 16546486
Drug: Placebo margarine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo margarine (0 g)
Trial: 12775317
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using topical methyl aminolevulinate (Metvix)
Trial: 6152058
Drug: RS 86,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RS 86, 0.5-4 mg orally
Trial: 6152058
Drug: RS 86,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RS 86, 4 mg orally
Trial: 30073931
Drug: Silymarin 420
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin 420 mg/day for one week after each doxorubicin dose
Trial: 30089301
Drug: Vancomycin (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (7 days, 1,500 mg/day)
Trial: 27456342
Drug: 1-week free
RxNorm normalized name: Free Cysteine
DrugBank: Cysteine (DB00151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-week free nicotine replacement therapy (NRT) sample and medication counselling
Trial: 23477217
Drug: Systemic enzyme
RxNorm normalized name: alpha-D-galactosidase enzyme Chewable Tablet [Beano]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic enzyme therapy in combination with antibiotics
Trial: 9360863
Drug: Ascending runs
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascending runs in sequential presentation
Trial: 9360863
Drug: Descending runs
RxNorm normalized name: Defend II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Descending runs in sequential presentation
Trial: 26365936
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard-dose clopidogrel)
Trial: 7570132
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg morphine sulphate in 20 ml saline (Group A)
Trial: 7570132
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.25% bupivacaine (Group B)
Trial: 7570132
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg morphine sulphate in 20 ml of 0.25% bupivacaine (Group C)
Trial: 7570132
Drug: No intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intra-articular injection (Group D)
Trial: 7400107
Drug: Sustained-release methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release methylphenidate (20 mg once daily)
Trial: 7400107
Drug: Standard methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard methylphenidate (10 mg twice daily)
Trial: 29691998
Drug: TEAR treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEAR treatment arms
Trial: 29691998
Drug: RACAT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RACAT treatment arms
Trial: 29691998
Drug: RACAT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RACAT treatment response
Trial: 28177481
Drug: Illicit drugs
RxNorm normalized name: Illicium difengpi bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Illicit drugs for pain relief
Trial: 19568178
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg LDECA plus 30 mg lansoprazole
Trial: 19568178
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg LDECA
Trial: 9894371
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose (LD) budesonide (400 micrograms twice daily for 6 weeks, then 400 micrograms nocte for 12 weeks)
Trial: 9894371
Drug: Static dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static dose (SD) budesonide (400 micrograms nocte for 18 weeks)
Trial: 9894371
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose (LD) budesonide (400 micrograms twice daily for 6 weeks)
Trial: 8115156
Drug: ProCell (DexSol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProCell (DexSol with hEGF and insulin)
Trial: 21900193
Drug: Weekly bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly bortezomib induction followed by bortezomib-based maintenance
Trial: 15341437
Drug: Steroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid therapy (specific type and dosage not detailed)
Trial: 9692272
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/24 h for the first 6 months)
Trial: 31012599
Drug: Nasal saline
RxNorm normalized name: Nasal Saline
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal saline irrigation (NSI) daily for 12 weeks
Trial: 23549225
Drug: Duloxetine (30-90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (30-90 mg for 12 weeks)
Trial: 21720661
Drug: Dapsone gel
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone gel 5% + tazarotene cream 0.1%
Trial: 12734506
Drug: Tazarotene cream
RxNorm normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene cream 0.1%
Trial: 16488295
Drug: Low-dose UVA1
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose UVA1 (20 J/cm2)
Trial: 16488295
Drug: Medium-dose UVA1
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose UVA1 (50 J/cm2)
Trial: 8462386
Drug: Captopril (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (initial dose: 12.5 mg daily, increased according to tolerance)
Trial: 2939220
Drug: Ketanserin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (20 mg twice daily for 15 days, then 40 mg twice daily for 75 days)
Trial: 2939220
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg twice daily for 90 days)
Trial: 15198156
Drug: Epidural anaesthesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural anaesthesia (75 mg bupivacaine heavy + 50 microg fentanyl)